Drug recall · September 25, 2019
Anagrelide Capsules recall
Why: Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in India for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-453-01.
- Lots / codes
Lot #: BFE2E003, Exp 08/31/2020
- Quantity
- 2472 bottles
- Company
- Torrent Pharma Inc., Basking Ridge, NJ
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- September 6, 2019 · Voluntary: Firm initiated
- Classified
- September 16, 2019
- Reported
- September 25, 2019
- Ended
- November 3, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Anagrelide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.